Loberamisal stroke trial reports better 90-day recovery, with confirmation needed

JAMA published results from the LAIS stroke trial on September 10, reporting that loberamisal improved the likelihood of a favorable functional outcome three months after ischemic stroke. The findings concern an outcome central to healthspan: how much disability remains after a major vascular event.

The publication brings fuller scrutiny to results previously presented at the 2026 International Stroke Conference. The American Heart Association’s conference summary had reported an approximately 13-percentage-point absolute improvement in excellent functional outcomes. The new journal report and accompanying editorial make the limitations especially relevant to interpreting that signal.

What the trial found

LAIS was a randomized, double-blind, placebo-controlled phase 3 trial at 32 hospitals in China. Investigators randomized 998 adults; 997 received study treatment and entered the primary analysis. Median age was 64. Enrollment occurred in 2024, with final follow-up in April 2025.

Participants received intravenous loberamisal or placebo alongside standard stroke care, starting within 48 hours of symptom onset. At 90 days, 69.7% in the loberamisal group versus 56.3% receiving placebo reached a modified Rankin Scale score of 0 or 1, indicating no symptoms or no significant disability. The reported absolute difference was 13.28 percentage points, with a 95% confidence interval of 7.24 to 19.32.

Serious adverse events occurred in 8.6% and 10.7%, respectively. Several secondary measures, including early neurological improvement and a measure of daily functioning, showed no significant difference. That inconsistency limits how broadly the primary result can be interpreted.

Why independent confirmation matters

In the accompanying editorial, UCLA neurologist Jeffrey L. Saver describes the continuing need for therapies that protect brain cells or support repair after blood flow is interrupted. Restoring circulation can leave substantial disability, and decades of attempts to translate neuroprotective treatments into reliable clinical benefits have repeatedly disappointed.

Saver identifies several reasons for caution. Patients undergoing mechanical clot removal were excluded, leaving unanswered whether loberamisal would complement that treatment. Outcomes were assessed by local investigators rather than central raters. Although investigators were blinded, the editorial notes that potential assessment bias cannot be completely dismissed.

The treatment’s extended infusion course also raises implementation questions in health systems with shorter hospital stays. Its duration makes it difficult to distinguish early protection from later repair as the explanation for any benefit.

Saver calls for independent analysis of participant-level data and replication in multinational trials. These are substantive tests of whether the result can travel across populations and care settings.

Recovery is a healthspan outcome

CDC guidance describes stroke recovery as a process that can take weeks, months or years. Persistent effects can include weakness, difficulties with speech and memory, swallowing problems and reduced ability to carry out everyday activities. Some survivors recover fully; others experience lifelong disability.

Rehabilitation therefore spans several disciplines. Speech therapy addresses communication, physical therapy supports movement and coordination, and occupational therapy focuses on activities such as dressing, bathing and eating. Prevention of another stroke remains another part of continuing care, including management of associated cardiovascular and metabolic conditions.

That broader context explains why functional recovery deserves attention alongside survival. For this trial, however, a favorable score at three months leaves longer-term questions open. Evidence that an intervention improves one recovery threshold must still be tested against other measures, independent confirmation and the realities of routine care.